Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 billion
Profitability
Miscellaneous
Employees2,910
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) announced its earnings results on Monday, August, 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The company earned $699.71 million during the quarter, compared to the consensus estimate of $694.60 million. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The company's revenue was down 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.76 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
What guidance has Endo International issued on next quarter's earnings?
Endo International updated its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.86 billion.
What price target have analysts set for ENDP?
15 equities research analysts have issued 12-month price targets for Endo International's shares. Their predictions range from $2.00 to $15.00. On average, they anticipate Endo International's stock price to reach $8.25 in the next year. This suggests a possible upside of 184.5% from the stock's current price. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings, 11 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
Has Endo International been receiving favorable news coverage?
Media coverage about ENDP stock has been trending positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endo International earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Endo International.
Are investors shorting Endo International?
Endo International saw a increase in short interest in July. As of July 31st, there was short interest totalling 28,757,700 shares, an increase of 13.4% from the June 30th total of 25,352,200 shares. Based on an average daily trading volume, of 5,340,000 shares, the days-to-cover ratio is presently 5.4 days. Currently, 14.3% of the company's shares are sold short. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Agios Pharmaceuticals (AGIO), Myokardia (MYOK), Xencor (XNCR), Reata Pharmaceuticals (RETA), Zogenix (ZGNX), Emergent Biosolutions (EBS), Uniqure (QURE), Zai Lab (ZLAB), Intercept Pharmaceuticals (ICPT), Akcea Therapeutics (AKCA), Biohaven Pharmaceutical (BHVN), Cambrex (CBM), Portola Pharmaceuticals (PTLA), Apellis Pharmaceuticals (APLS) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of Endo International own?
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)
Who are Endo International's major shareholders?
Endo International's stock is owned by many different of retail and institutional investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (1.35%), Bank of New York Mellon Corp (1.07%), Diamond Hill Capital Management Inc. (0.48%), Panagora Asset Management Inc. (0.42%), Acadian Asset Management LLC (0.15%) and New York State Teachers Retirement System (0.14%). Company insiders that own Endo International stock include Nancy J Hutson, Roger H Kimmel and William P Montague. View Institutional Ownership Trends for Endo International.
Which institutional investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Acadian Asset Management LLC, Diamond Hill Capital Management Inc., Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, BNP Paribas Arbitrage SA, New York State Teachers Retirement System and Comerica Bank. Company insiders that have sold Endo International company stock in the last year include Nancy J Hutson, Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International.
Which institutional investors are buying Endo International stock?
ENDP stock was purchased by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Systematic Financial Management LP, Russell Investments Group Ltd., Hunter Associates Investment Management LLC, Paloma Partners Management Co, Commonwealth Bank of Australia, UBS Asset Management Americas Inc. and United Services Automobile Association. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $2.90.
How big of a company is Endo International?
Endo International has a market capitalization of $656.53 million and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe.View Additional Information About Endo International.
What is Endo International's official website?
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
